Saint Louis, Missouri 63110

  • Breast Cancer

Purpose:

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors plan the best treatment. PURPOSE: This research study is looking at tissue samples from women who underwent chemotherapy for lymph node-positive stage II or stage IIIA breast cancer.


Study summary:

OBJECTIVES: Primary - To identify biomarkers that can be used to individually tailor the use of adjuvant dose-dense therapy in women with stage II or IIIA breast cancer. Secondary - To identify groups of patients who have a poor prognosis despite adjuvant chemotherapy and who should be prospectively targeted for new approaches to adjuvant treatment. OUTLINE: This is a multicenter study. Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).


Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of node-positive breast cancer - Stage II-IIIA disease - Underwent adjuvant chemotherapy on trial CLB-9741 or CLB-9344 - Hormone receptor status not specified


NCT ID:

NCT00897026


Primary Contact:

Study Chair
Matthew Ellis, MD, PhD, FRCP
Washington University Siteman Cancer Center

Matthew Ellis, MD, PhD, FRCP
Phone: (713) 798-1999


Backup Contact:

N/A


Location Contact:

Saint Louis, Missouri 63110
United States

Matthew Ellis, MD, PhD, FRCP
Phone: (713) 798-1999

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.